Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation 
and epithelial barrier disruption

Wang,Xuewei; Fan,Fugang; Cao,Qin

doi:10.3892/mmr.2016.5358

Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption

Authors:
- Xuewei Wang
- Fugang Fan
- Qin Cao
View Affiliations

Affiliations: Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China
Published online on: June 2, 2016 https://doi.org/10.3892/mmr.2016.5358
Pages: 1173-1179
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory bowel diseases (IBDs) are chronic inflammatory gastrointestinal disorders caused by a dysregulated mucosal immune response and epithelial barrier disruption. Conventional treatment of IBD is currently limited to overcoming patient symptoms and is often associated with severe adverse effects from the drugs used. Modified Pulsatilla decoction has been used previously to treat ulcerative colitis (UC) in clinical practice in China, however, the underlying mechanism in the treatment of UC remains to be elucidated. In the present study, the efficiency and mechanisms of modified Pulsatilla decoction in the treatment of oxazolone‑induced colitis were investigated. Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice. Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues. In addition, modified Pulsatilla decoction suppressed the activation of the nuclear factor‑κB signaling pathway. Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

View Figures

View References

1	Baumgart DC and Carding SR: Inflammatory bowel disease: Cause and immunobiology. Lancet. 369:1627–1640. 2007. View Article : Google Scholar : PubMed/NCBI
2	Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007. View Article : Google Scholar : PubMed/NCBI
3	Baumgart DC and Sandborn WJ: Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
4	Nielsen OH: New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 1:32014.
5	Danese S: New therapies for inflammatory bowel disease: From the bench to the bedside. Gut. 61:918–932. 2012. View Article : Google Scholar
6	Hilsden RJ, Verhoef MJ, Rasmussen H, Porcino A and DeBruyn JC: Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis. 17:655–662. 2011. View Article : Google Scholar
7	Langmead L and Rampton DS: Review article: Complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 23:341–349. 2006. View Article : Google Scholar : PubMed/NCBI
8	Rahimi R, Mozaffari S and Abdollahi M: On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci. 54:471–480. 2009. View Article : Google Scholar
9	Jackson LN, Zhou Y, Qiu S, Wang Q and Evers BM: Alternative medicine products as a novel treatment strategy for inflammatory bowel disease. Am J Chin Med. 36:953–965. 2008. View Article : Google Scholar : PubMed/NCBI
10	Sałaga M, Zatorski H, Sobczak M, Chen C and Fichna J: Chinese herbal medicines in the treatment of IBD and colorectal cancer: A review. Curr Treat Options Oncol. 15:405–420. 2014. View Article : Google Scholar
11	Li R, Alex P, Ye M, Zhang T, Liu L and Li X: An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease. Int J Clin Exp Med. 4:309–319. 2011.PubMed/NCBI
12	Cao YB, Zhang JD, Diao YY, Yan L, Wang DJ, Jia XM, Gao PH, Cheng MH, Xu Z, Wang Y and Jiang YY: Effects of Changtai granules, a traditional compound Chinese medicine, on chronic trinitrobenzene sulfonic acid-induced colitis in rats. World J Gastroenterol. 11:3539–3543. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X and Tang T: Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 108:90–98. 2013. View Article : Google Scholar :
14	Zhang F, Li Y, Xu F, Chu Y and Zhao W: Comparison of Xilei-san, a Chinese herbal medicine and dexamethasone in mild/moderate ulcerative proctitis: A double-blind randomized clinical trial. J Altern Complement Med. 19:838–842. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hu Y, Chen X, Duan H, Hu Y and Mu X: Pulsatilla decoction and its active ingredients inhibit secretion of NO, ET-1, TNF-alpha and IL-1 alpha in LPS-induced rat intestinal microvascular endothelial cells. Cell Biochem Funct. 27:284–288. 2009. View Article : Google Scholar : PubMed/NCBI
16	Cheng L, Zhang M, Zhang P, Song Z, Ma Z and Qu H: Silver complexation and tandem mass spectrometry for differentiation of triterpenoid saponins from the roots of Pulsatilla Chinensis (Bunge) Regel. Rapid Commun Mass Spectrom. 22:3783–3790. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tan B, Ma Y, Shi R and Wang T: Simultaneous quantification of three alkaloids of Coptidis Rhizoma in rat urine by high-performance liquid chromatography: Application to pharmacokinetic study. Biopharm Drug Dispos. 28:511–516. 2007. View Article : Google Scholar : PubMed/NCBI
18	Chan CO, Chu CC, Mok DK and Chau FT: Analysis of berberine and total alkaloid content in cortex phellodendri by near infrared spectroscopy (NIRS) compared with high-performance liquid chromatography coupled with ultra-visible spectrometric detection. Anal Chim Acta. 592:121–131. 2007. View Article : Google Scholar : PubMed/NCBI
19	Shi Z, Zhu X and Zhang H: Micelle-mediated extraction and cloud point preconcentration for the analysis of aesculin and aesculetin in Cortex fraxini by HPLC. J Pharm Biomed Anal. 44:867–873. 2007. View Article : Google Scholar : PubMed/NCBI
20	Muluye RA, Bian Y and Alemu PN: Anti-inflammatory and antimicrobial effects of heat-clearing Chinese herbs: A current review. J Tradit Complement Med. 4:93–98. 2014. View Article : Google Scholar : PubMed/NCBI
21	Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS and Strober W: Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629–638. 2002. View Article : Google Scholar : PubMed/NCBI
22	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the care and use of laboratory animals. 8th edition. National Academies Press; Washington, D.C., USA: 2011
23	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
24	León AJ, Gómez E, Garrote JA, Bernardo D, Barrera A, Marcos JL, Férnandez-Salazar L, Velayos B, Blanco-Quirós A and Arranz E: High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm. 2009:302009. View Article : Google Scholar
25	Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA and Peyron JF: Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell. 86:787–798. 1996. View Article : Google Scholar : PubMed/NCBI
26	Kojima R, Kuroda S, Nakamaru K and Hatakeyama S: Oxazolone-induced colitis in BALB/C mice: A new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. J Pharmacol Sci. 96:307–313. 2004. View Article : Google Scholar : PubMed/NCBI
27	Svartz N: Salazopyrin a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand. 11:557–590. 1942.
28	Kornbluth A and Sachar DB; Practice Parameters Committee of the American College of Gastroenterology: Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 105:501–523; quiz 524. 2010. View Article : Google Scholar : PubMed/NCBI
29	Khor B, Gardet A and Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature. 474:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
30	Strober W and James SP: The immunologic basis of inflammatory bowel disease. J Clin Immunol. 6:415–432. 1986. View Article : Google Scholar : PubMed/NCBI
31	Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C and Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 157:1261–1270. 1996.PubMed/NCBI
32	Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Burgel N, Fromm M, et al: Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis and cell restitution. Gastroenterology. 129:550–564. 2005. View Article : Google Scholar : PubMed/NCBI
33	Hering NA, Fromm M and Schulzke JD: Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol. 590:1035–1044. 2012. View Article : Google Scholar : PubMed/NCBI
34	Suzuki T: Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 70:631–659. 2013. View Article : Google Scholar
35	Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 9:799–809. 2009. View Article : Google Scholar : PubMed/NCBI
36	Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, Wang Y and Turner JR: Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 285:12037–12046. 2010. View Article : Google Scholar : PubMed/NCBI
37	Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT and Collins JE: Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest. 85:1139–1162. 2005. View Article : Google Scholar : PubMed/NCBI
38	Schreiber S, Nikolaus S and Hampe J: Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 42:477–484. 1998. View Article : Google Scholar : PubMed/NCBI
39	Neurath MF, Becker C and Barbulescu K: Role of NF-kappaB in immune and inflammatory responses in the gut. Gut. 43:856–860. 1998. View Article : Google Scholar : PubMed/NCBI
40	Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA and Said HM: TNF-alpha-induced-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol. 286:G367–G376. 2004. View Article : Google Scholar : PubMed/NCBI
41	Beutheu Youmba S, Belmonte L, Galas L, Boukhettala N, Bôle-Feysot C, Déchelotte P and Coëffier M: Methotrexate modulates tight junctions through NF-κB, MEK, and JNK Pathways. J Pediatr Gastroenterol Nutr. 54:463–470. 2012. View Article : Google Scholar